Nomenclature
Short Name:
CDKL4
Full Name:
Cyclin-dependent kinase-like 4
Alias:
- AA626859
Classification
Type:
Protein-serine/threonine kinase
Group:
CMGC
Family:
CDKL
SubFamily:
NA
Structure
Mol. Mass (Da):
36,223
# Amino Acids:
315
# mRNA Isoforms:
2
mRNA Isoforms:
43,384 Da (379 AA; Q5MAI5); 36,223 Da (315 AA; Q5MAI5-2)
4D Structure:
NA
1D Structure:
Subfamily Alignment
Domain Distribution:
| Start | End | Domain |
|---|---|---|
| 4 | 286 | Pkinase |
Post-translation Modifications
For detailed information on phosphorylation of this kinase go to PhosphoNET
Acetylated:
K33.
Tyrosine phosphorylated:
Y160+.
Distribution
Based on gene microarray analysis from the NCBI
Human Tissue Distribution
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
-
-
-
-
0.4
3
3
1
-
-
-
-
0.3
2
3
2
0.3
2
3
0
0.1
1
3
0
0.1
1
3
0
0.1
1
3
0
0.1
1
3
0
0.3
2
3
1
0.3
2
3
1
-
-
-
-
0.3
2
3
0
0.1
1
3
0
-
-
-
-
0.3
2
3
1
0.1
1
3
0
0.4
3
3
2
0.3
2
3
1
0.1
1
3
1
0.1
1
3
1
-
-
-
-
0.9
7
3
1
0.6
5
3
6
0.1
1
3
1
0.3
2
3
0
0.1
1
3
0
0.3
2
3
0
-
-
-
-
100
790
12
53
-
-
-
-
-
-
-
-
-
-
-
-
8
64
9
59
Evolution
Species Conservation
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
100
100
100
0
0
97
79.8
81.2
95
-
-
94
-
-
-
80.3
83.1
93
-
-
-
83.3
90
91
62.7
76.6
90
-
-
-
62.5
75.8
-
38.4
57.4
-
38
60
-
64
77.7
-
-
-
-
38.7
51.5
-
51.4
67
-
53.8
70.5
-
56.4
71
-
-
-
-
35.8
56.8
-
-
-
-
-
-
-
-
-
-
-
-
-
For a wider analysis go to PhosphoNET Evolution in PhosphoNET
Regulation
Activation:
Likely that phosphorylation at Tyr-160 is required for catalytic activity based on homology with other CDK's.
Inhibition:
Likely that phosphorylation at Tyr-15 is inhibitory based on homology with other CDK's.
Synthesis:
NA
Degradation:
NA
Protein Kinase Specificity
Matrix of observed frequency (%) of amino acids in aligned protein substrate phosphosites
Matrix Type:
Predicted from the application of the Kinexus Kinase Substrate Predictor Version 2.0 algorithm, which was trained with over 10,000 kinase-protein substrate pairs and 8,000 kinase-peptide substrate pairs.
Domain #:
1
Disease Linkage
Comments:
The low rate of reported somatic mutations, but broad and multi-site in CDKL4 indicates that it may function as a tumour requiring protein (TRP) in human tumours.
Gene Expression in Cancers:
The COSMIC website notes an up-regulated expression score for CDKL4 in diverse human cancers of 350, which is 0.8-fold of the average score of 462 for the human protein kinases. The down-regulated expression score of 0 for this protein kinase in human cancers was 100% lower than the average score of 60 for the human protein kinases.
Mutagenesis Experiments:
Insertional mutagenesis studies in mice have not yet revealed a role for this protein kinase in mouse cancer oncogenesis.
Mutation Rate in All Cancers:
Percent mutation rates per 100 amino acids length in human cancers: 0.07 % in 24726 diverse cancer specimens. This rate is only -13 % lower than the average rate of 0.075 % calculated for human protein kinases in general.
Mutation Rate in Specific Cancers:
Highest percent mutation rates per 100 amino acids length in human cancers: 0.32 % in 603 endometrium cancers tested; 0.22 % in 864 skin cancers tested.
Frequency of Mutated Sites:
None > 3 in 20,009 cancer specimens
Comments:
Only 1 insertion, and no deletions or complex mutations are noted on the COSMIC website.